C-MET Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the C-MET Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's C-MET Non-Small Cell Lung Cancer Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for C-MET Non-Small Cell Lung Cancer.
• The leading C-MET Non-Small Cell Lung Cancer Companies working in the market include AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• Promising C-MET Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include PF-02341066, Telisotuzumab vedotin, Amivantamab, Lazertinib, Carboplatin, Pemetrexed, PLB1001, and others.
• May 2024:- Apollomics Inc.- Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.
• May 2024:- AbbVie- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
• April 2024:- AstraZeneca- A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib. This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib.

To explore more information on the latest breakthroughs in the M C-MET Non-Small Cell Lung Cancer treatment landscape of the report, click here @ C-MET Non-Small Cell Lung Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

C-MET Non-Small Cell Lung Cancer Overview
The role of the c-mesenchymal-epithelial transition factor (C-MET) signaling pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors have shown anti-tumor activity in Non-Small Cell Lung Cancer both in preclinical and in clinical trials. However, given the molecular heterogeneity of Non-Small Cell Lung Cancer, it is likely that only a specific subset of Non-Small Cell Lung Cancer patients will benefit from c-MET inhibitors. Emerging data also suggest that MET inhibitors in combination with EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) may have a role in therapy for both EGFR-TKI resistant and EGFR-TKI naïve patients. c-Met is known to be overexpressed, mutated and gene amplified, specifically in NSCLC, and has also been implicated in the development of resistance against other small-molecule inhibitors (e.g. EGFR).

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Emerging Drugs

• JNJ-61186372: Janssen Research & Development, LLC
JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen's licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.

• PLB1001 - Beijing Pearl Biotechnology Limited Liability Company
PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

For further information, refer to the detailed C-MET Non-Small Cell Lung Cancer Unmet Needs, C-MET Non-Small Cell Lung Cancer Market Drivers, and C-MET Non-Small Cell Lung Cancer Market Barriers, click here for C-MET Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

C-MET Non-Small Cell Lung Cancer Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC). The companies which have their C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, etc.

DelveInsight's C-MET Non-Small Cell Lung Cancer pipeline report covers around 20+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Request a sample and discover the recent advances in C-MET Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ C-MET Non-Small Cell Lung Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Intramuscular
• Intratumoral
• Intravenous
• Molecule Type

C-MET Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules
• Product Type

Dive deep into rich insights for drugs for C-MET Non-Small Cell Lung Cancer Pipeline, click here @ C-MET Non-Small Cell Lung Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the C-MET Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• C-MET Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• C-MET Non-Small Cell Lung Cancer Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
• C-MET Non-Small Cell Lung Cancer Pipeline Therapies- PF-02341066, Telisotuzumab vedotin, Amivantamab, Lazertinib, Carboplatin, Pemetrexed, PLB1001, and others.

Got Queries? Find out the related information on C-MET Non-Small Cell Lung Cancer Mergers and acquisitions, C-MET Non-Small Cell Lung Cancer Licensing Activities @ C-MET Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
9. Mid Stage Products (Phase II)
10. Telisotuzumab: AbbVie
11. PLB1001: Beijing Pearl Biotechnology Limited Liability Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. JNJ-61186372: Janssen Research & Development, LLC
15. Drug profiles in the detailed report…..
16. Pre-clinical and Discovery Stage Products
17. Drug profiles in the detailed report…..
18. Inactive Products
19. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
20. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
21. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
22. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
23. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
24. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
25. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
26. Appendix

List of Important Links-

https://www.wowonder.xyz/read-blog/65223
https://diccut.com/germandennydones
https://us.newyorktimesnow.com/dennydones9193
https://www.mymeetbook.com/germanydennydones
https://wiwonder.com/1716272393254738_2674
https://www.japanesewomenorg.com/read-blog/15585
https://tannda.net/read-blog/62770
https://evahno.com/read-blog/22402
https://www.pickmemo.com/read-blog/307268
https://ai.ceo/read-blog/132421
https://www.truthsocialviet.com/read-blog/58205
https://hanzuzhisheng.com/read-blog/489
https://www.testimonyforgod.com/read-blog/3019
https://www.skillsire.com/germandennydones
https://meetplayer.com/8a48fed02
https://zekond.com/read-blog/37531
https://shareyoursocial.com/germanydennydones
https://www.snipesocial.co.uk/dennydones9911
https://social.studentb.eu/read-blog/182065

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.